Albert Chin, also known as Al, has a 36-year history in medical device development. He has a background in Mechanical Engineering and General Surgery, with a B.S. degree from MIT, an M.S. degree from Stanford University, an M.D. from UC San Francisco, and General Surgical residency training at UT Southwestern at Dallas, Parkland Memorial Hospital. He is a co-founder of Origin Medsystems, Inc., which was acquired by Eli Lilly and Company, and became Guidant Cardiac Surgery. He has developed products generating over $3.2 billion in revenue, including the Fogarty-Chin Linear Extrusion Catheter, the Fogarty-Chin Angioscopic Valvulotome, the Origin Cement Extraction System, the Origin Preperitoneal Dissection Balloon, the Origin Laparolift; and for cardiac surgery, the VasoView, Heartstring, and FLEXView devices. The VasoView device is standard of care in coronary artery bypass procedures, and it has been used in over 2.4 million patients to date. Albert is Co-founder of Pavilion Medical Innovations, LLC, a medical device incubator funded by Catalyst Health Ventures in Boston, and a principal in the following startup companies: Saphena Medical, Cruzar Medsystems, nVision Medical, and ChemoFilter. He holds 183 issued U.S. patents.